243 related articles for article (PubMed ID: 25050775)
61. Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)
Lin CW; Lee CY; Lin SY; Kang L; Fu YC; Chen CH; Wang CK
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142447
[TBL] [Abstract][Full Text] [Related]
62. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
63. Upregulation of Mir-34a in AGS Gastric Cancer Cells by a PLGA-PEG-PLGA Chrysin Nano Formulation.
Mohammadian F; Abhari A; Dariushnejad H; Zarghami F; Nikanfar A; Pilehvar-Soltanahmadi Y; Zarghami N
Asian Pac J Cancer Prev; 2015; 16(18):8259-63. PubMed ID: 26745070
[TBL] [Abstract][Full Text] [Related]
64. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
65. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Vangara KK; Liu JL; Palakurthi S
Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
[TBL] [Abstract][Full Text] [Related]
66. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
Liu P; Yu H; Sun Y; Zhu M; Duan Y
Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
[TBL] [Abstract][Full Text] [Related]
67. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
68. Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.
Jiang X; Xin H; Gu J; Du F; Feng C; Xie Y; Fang X
J Pharm Sci; 2014 May; 103(5):1487-96. PubMed ID: 24619482
[TBL] [Abstract][Full Text] [Related]
69. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery.
Kohler N; Sun C; Fichtenholtz A; Gunn J; Fang C; Zhang M
Small; 2006 Jun; 2(6):785-92. PubMed ID: 17193123
[TBL] [Abstract][Full Text] [Related]
70. PEGylation strategies for active targeting of PLA/PLGA nanoparticles.
Betancourt T; Byrne JD; Sunaryo N; Crowder SW; Kadapakkam M; Patel S; Casciato S; Brannon-Peppas L
J Biomed Mater Res A; 2009 Oct; 91(1):263-76. PubMed ID: 18980197
[TBL] [Abstract][Full Text] [Related]
71. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery.
Cu Y; Booth CJ; Saltzman WM
J Control Release; 2011 Dec; 156(2):258-64. PubMed ID: 21763739
[TBL] [Abstract][Full Text] [Related]
72. Surface analysis of PEGylated nano-shields on nanoparticles installed by hydrophobic anchors.
Ebbesen MF; Whitehead B; Ballarin-Gonzalez B; Kingshott P; Howard KA
Pharm Res; 2013 Jul; 30(7):1758-67. PubMed ID: 23579480
[TBL] [Abstract][Full Text] [Related]
73. Cholesterol-modified poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery.
Lee JJ; Lee SY; Park JH; Kim DD; Cho HJ
Int J Pharm; 2016 Jul; 509(1-2):483-491. PubMed ID: 27286639
[TBL] [Abstract][Full Text] [Related]
74. In situ gelation of PEG-PLGA-PEG hydrogels containing high loading of hydroxyapatite: in vitro and in vivo characteristics.
Lai MC; Chang KC; Hsu SC; Chou MC; Hung WI; Hsiao YR; Lee HM; Hsieh MF; Yeh JM
Biomed Mater; 2014 Feb; 9(1):015011. PubMed ID: 24457223
[TBL] [Abstract][Full Text] [Related]
75. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
76. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
Kang T; Gao X; Hu Q; Jiang D; Feng X; Zhang X; Song Q; Yao L; Huang M; Jiang X; Pang Z; Chen H; Chen J
Biomaterials; 2014 May; 35(14):4319-32. PubMed ID: 24565520
[TBL] [Abstract][Full Text] [Related]
77. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
78. PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications.
Zhang K; Tang X; Zhang J; Lu W; Lin X; Zhang Y; Tian B; Yang H; He H
J Control Release; 2014 Jun; 183():77-86. PubMed ID: 24675377
[TBL] [Abstract][Full Text] [Related]
79. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
80. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
